Synonyms: NBI-921352 | NBI921352 | XEN-901 | XEN901
Compound class:
Synthetic organic
Comment: Zandatrigine (NBI-921352) is reported as a NaV1.6 (SCN8A) selective sodium channel inhibitor that is proposed for antiepileptic activity [2].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, White HS. (2018)
Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia, 59 (10): 1811-1841. [PMID:30368792] |
2. Johnson JP, Focken T, Khakh K, Tari PK, Dube C, Goodchild SJ, Andrez JC, Bankar G, Bogucki D, Burford K et al.. (2022)
NBI-921352, a first-in-class, NaV1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats. Elife, 11: e72468. DOI: 10.7554/eLife.72468 [PMID:35234610] |